All In Biotech

Drug Trial Radar · NCT06805825

A Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced and/or Metastatic Solid Tumors Known to Express c-Kit

A Phase 1 Dose Escalation and Expansion Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 in Subjects With Advanced and/or Metastatic Solid Tumors Known to Express c-Kit

Last checked: Nov 20, 2026Latest source record: Nov 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

67

Planned (sponsor's estimate)

Start

Feb 3, 2025

Primary completion

Aug 30, 2027

Study completion Dec 31, 2027

Sponsor

Lead sponsor
Novelty Nobility, Inc.Industry
Sponsor type
Industry
First posted
Feb 3, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This open-label clinical trial will evaluate the safety and tolerability of NN3201 in subjects with advanced and/or metastatic solid tumors known to express c-Kit.

Conditions

  • Gastrointestinal Stromal Tumors
  • Small-cell Lung Cancer
  • Adenoid Cystic Carcinoma
  • Uveal Melanoma
  • Neuroendocrine Tumors
  • Chromophobe Renal Cell Carcinoma
  • Clear Cell Renal Cell Carcinoma

Interventions

  • NN3201Drug

    A c-Kit targeting fully human monoclonal antibody-drug conjugate with MMAE administered intravenously.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of subjects with Dose-limiting Toxicities:Time frame: 3 weeks
  2. Incidence of Adverse Events:Time frame: 1 year

Locations

5 sites in 1 country. Site status is shown where the registry gives one.

  • University of Michigan Hospitals

    Ann Arbor, Michigan · Recruiting

  • Case Comprehensive Cancer Center

    Cleveland, Ohio · Recruiting

  • Oregon Health & Science University

    Portland, Oregon · Recruiting

  • The University of Texas MD Anderson Cancer Center

    Houston, Texas · Recruiting

  • NEXT Virginia

    Fairfax, Virginia · Active not recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.